Weight management semaglutide, Johannesburg
Wegovy and weight management semaglutide in Johannesburg.
Wegovy contains semaglutide at weight management doses. We assess whether it is clinically appropriate, then supervise treatment with metabolic testing, body composition tracking and structured review.
In short
Wegovy is semaglutide prescribed at weight management doses, given as a weekly injection. It reduces appetite and can support meaningful weight loss when combined with nutrition, protein and resistance training. It is prescription only, is not suitable for everyone, and requires medical assessment and monitoring. Registered indications, doses and available formulations differ between products and jurisdictions. We assess suitability in Waverley, Johannesburg, then supervise treatment and review progress with blood tests and body composition analysis.
Medically reviewed by Dr Arnav Kapur, MBBCh Cum Laude
The approach
Understand first. Then treat.
Weight management doses of semaglutide were studied specifically for obesity and overweight with weight related complications. The medicine reduces appetite, but the outcome depends heavily on what surrounds it.
We treat weight as a metabolic and hormonal problem. That means understanding insulin resistance, thyroid function, hormones, sleep, stress and body composition before deciding whether medication is part of the answer.
How treatment is structured
- Medical assessment, examination and screening for contraindications
- Baseline blood panel covering glucose, insulin, HbA1c, lipids, thyroid, liver and kidney function
- Bioimpedance body composition analysis at baseline and through treatment
- Gradual dose titration with active management of nausea and gastrointestinal effects
- Protein, nutrition and resistance training targets to minimise unnecessary lean-mass loss
- Scheduled reviews, with a defined maintenance plan
Wegovy compared with Ozempic
Both contain semaglutide. They differ in dose range and registered indication, and availability in South Africa varies. We discuss which product is clinically appropriate for you, and what is actually obtainable, without promising a brand in advance.
Who should not use it
Semaglutide is avoided in pregnancy and breastfeeding, and in people with a personal or family history of medullary thyroid carcinoma or MEN2. Caution applies with pancreatitis, significant gastrointestinal disease, gallbladder disease and certain other medicines. Screening for these is part of the assessment.
Measuring more than weight
We track fat mass, muscle mass, waist circumference, blood pressure, glucose, insulin and lipids. This shows whether treatment is improving metabolic health and healthy ageing, not only the number on a scale.
Keeping the result
Appetite signalling returns when treatment stops. Maintenance is planned from the beginning, with nutrition, strength training, sleep and ongoing medical review so progress is sustainable.
Common questions
Answers before you book.
Is Wegovy available in South Africa?
Availability of specific semaglutide products changes over time. We assess you clinically and then discuss which registered options are appropriate and obtainable.
Do I need to be a certain weight to qualify?
Weight management prescribing generally follows BMI thresholds, with lower thresholds where weight related conditions are present. Your suitability is determined by clinical assessment rather than a number alone.
Will I regain the weight if I stop?
Regain is common when treatment stops without a plan. We build maintenance into your care from the start to reduce that risk.
This page is general health information about a prescription medicine and is not medical advice, a prescription or an offer to supply. Treatment follows individual clinical assessment, and no outcome is guaranteed.
Ready to start properly?
Centre of Advanced Medicine, 13 Scott St, Waverley, Johannesburg
Monday to Friday, 07:40 to 17:00
011 440 8721